You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Fig. 4

Impact of neoadjuvant chemotherapy on immune infiltrates. (a) Boxplot diagrams presenting number of CD8 positive cells per mm2 in all patients separated according to their localization (invasive margin, tumor core and total). (b) Graphics showing the number of CD8+ cells per mm2 before and after neoadjuvant chemotherapy. “Before” is the diagnostic liver biopsy while “after” is the metastasis surgery following neoadjuvant procedure. (c)(d) Boxplot diagrams presenting number of CD8 positive cells per mm2 in patients with wild type RAS status and the neoadjuvant treatment separated according to localization (invasive margin, tumor core and total) and the treatment. (e)(f) Boxplot diagrams presenting number of CD8 positive cells per mm2 in patients with RAS mutated status and the neoadjuvant treatment separated according to localization (invasive margin, tumor core and total) and the treatment (N: no neoadjuvant chemotherapy, C: neoadjuvant chemotherapy, Ox: oxaliplatin, E: anti-EGFR, V: anti-VEGF, WT: wild type, Mu: mutated, n.s: not significant, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001)

Back to article page